Protocol Ledger

NCT06389474 · Phase III · RECRUITING

Efficacy of INM004 in Children With STEC-HUS

Interventional Phase III clinical trial protocol NCT06389474 sponsored by Inmunova in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-05 Enrollment: 220 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06389474
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06389474
Protocol FieldVerified Registry Value
NCT IdentifierNCT06389474
Consolidated Lead SponsorInmunova
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment220 participants (ESTIMATED)
Registered Start Date2024-10-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06389474
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
CHU NantesNantes, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI